Tesamorelin + Ipamorelin

▸ Overview

The Tesamorelin + Ipamorelin combination joins the stabilized GHRH effect of Tesamorelin with the selective GHRP stimulus of Ipamorelin. It is researched especially in the context of body composition and fat metabolism.

▸ Mechanism of action

• Combines the GHRH analog with the greatest clinical stability (Tesamorelin) with the most selective GHRP (Ipamorelin).
• Tesamorelin provides potent pituitary stimulation oriented toward visceral-fat reduction.
• Ipamorelin triggers GH pulses without raising cortisol, preserving Tesamorelin's clean metabolic profile.
• The GHRH/GHRP synergy maximizes GH release and effects on body composition.
• A combination especially researched in the context of lipodystrophy and metabolic syndrome.

▸ Administration

• Subcutaneous route: each component separately or pre-mixed.
• Fine needles in the abdomen or thigh.
• Storage: mandatory refrigeration (2–8 °C).

▸ Timing

• Before sleep is the most common schedule.
• Prior fasting of at least 2 hours.
• 30 minutes post-injection before food.

▸ Dosing & cycles

• Cycles: 8–26 weeks with monitoring of IGF-1 and blood glucose.
• Tesamorelin has a special metabolic profile; cycles are longer.
• Daily frequency is usual.

▸ Combinations

• Compatible with AOD-9604 for metabolic research.
• MK-677 can be added for a sustained synergistic effect.

▸ Disclaimer

▸ Products